{"id":"https://openalex.org/W4417017289","doi":"https://doi.org/10.1182/blood-2025-815","title":"Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results","display_name":"Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results","publication_year":2025,"publication_date":"2025-11-03","ids":{"openalex":"https://openalex.org/W4417017289","doi":"https://doi.org/10.1182/blood-2025-815"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2025-815","doi":"https://doi.org/10.1182/blood-2025-815","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2025-815","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019014469","display_name":"Claire Roddie","orcid":"https://orcid.org/0000-0002-4901-5858","observed_orcids":["https://orcid.org/0000-0002-4901-5858"]},"institutions":[{"id":"https://openalex.org/I1289784979","display_name":"University College Hospital","ror":"https://ror.org/00wrevg56","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289784979","https://openalex.org/I1340918713"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Claire Roddie","raw_affiliation_strings":["1University College London, London, United Kingdom","2University College London Hospital, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University College London, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]},{"raw_affiliation_string":"2University College London Hospital, London, United Kingdom","institution_ids":["https://openalex.org/I1289784979","https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082185560","display_name":"Maria Jos\u00e9 Leandro","orcid":"https://orcid.org/0000-0002-2254-4610","observed_orcids":["https://orcid.org/0000-0002-2254-4610","https://orcid.org/0000-0002-4631-9610"]},"institutions":[{"id":"https://openalex.org/I1289784979","display_name":"University College Hospital","ror":"https://ror.org/00wrevg56","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289784979","https://openalex.org/I1340918713"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Maria Leandro","raw_affiliation_strings":["1University College London, London, United Kingdom","2University College London Hospital, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University College London, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]},{"raw_affiliation_string":"2University College London Hospital, London, United Kingdom","institution_ids":["https://openalex.org/I1289784979","https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102728380","display_name":"Ben Parker","orcid":"https://orcid.org/0000-0001-7959-6529","observed_orcids":["https://orcid.org/0000-0001-7959-6529"]},"institutions":[{"id":"https://openalex.org/I2801926401","display_name":"Manchester Royal Infirmary","ror":"https://ror.org/03kr30n36","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801926401","https://openalex.org/I4210092852"]},{"id":"https://openalex.org/I4405271435","display_name":"NIHR Manchester Clinical Research Facility","ror":"https://ror.org/02e706q76","country_code":"GB","type":"facility","lineage":["https://openalex.org/I4405271435"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ben Parker","raw_affiliation_strings":["3NIHR Manchester CRF, Manchester Royal Infirmary, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3NIHR Manchester CRF, Manchester Royal Infirmary, Manchester, United Kingdom","institution_ids":["https://openalex.org/I2801926401","https://openalex.org/I4405271435"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071608606","display_name":"Eleni Tholouli","orcid":"https://orcid.org/0000-0002-4940-639X","observed_orcids":["https://orcid.org/0000-0002-4940-639X"]},"institutions":[{"id":"https://openalex.org/I2801926401","display_name":"Manchester Royal Infirmary","ror":"https://ror.org/03kr30n36","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801926401","https://openalex.org/I4210092852"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Eleni Tholouli","raw_affiliation_strings":["4Manchester Royal Infirmary, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Manchester Royal Infirmary, Manchester, United Kingdom","institution_ids":["https://openalex.org/I2801926401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070674274","display_name":"David R.W. Jayne","orcid":"https://orcid.org/0000-0002-1712-0637","observed_orcids":["https://orcid.org/0000-0002-1712-0637","https://orcid.org/0000-0002-8725-3283"]},"institutions":[{"id":"https://openalex.org/I2802466933","display_name":"Cambridge University Hospitals NHS Foundation Trust","ror":"https://ror.org/04v54gj93","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2802466933"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David Jayne","raw_affiliation_strings":["5Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I2802466933"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079539291","display_name":"Ben Uttenthal","orcid":"https://orcid.org/0000-0002-5340-2527","observed_orcids":["https://orcid.org/0000-0002-5340-2527"]},"institutions":[{"id":"https://openalex.org/I2802466933","display_name":"Cambridge University Hospitals NHS Foundation Trust","ror":"https://ror.org/04v54gj93","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2802466933"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ben Uttenthal","raw_affiliation_strings":["5Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I2802466933"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057258888","display_name":"Josefina Cort\u00e9s-Hern\u00e1ndez","orcid":"https://orcid.org/0000-0003-4538-3538","observed_orcids":["https://orcid.org/0000-0003-4538-3538"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Josefina Cort\u00e9s-Hern\u00e1ndez","raw_affiliation_strings":["6Hospital Universitari Vall d'Hebron-Universitat Aut\u00f3noma de Barcelona, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Hospital Universitari Vall d'Hebron-Universitat Aut\u00f3noma de Barcelona, Barcelona, Spain","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040138933","display_name":"Pere Barba","orcid":"https://orcid.org/0000-0001-7076-7969","observed_orcids":["https://orcid.org/0000-0001-7076-7969","https://orcid.org/0000-0003-1038-5197"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Pere Barba","raw_affiliation_strings":["6Hospital Universitari Vall d'Hebron-Universitat Aut\u00f3noma de Barcelona, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Hospital Universitari Vall d'Hebron-Universitat Aut\u00f3noma de Barcelona, Barcelona, Spain","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110218637","display_name":"Jose Andr\u00e9s Rom\u00e1n Ivorra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019010403","display_name":"Hospital Universitari i Polit\u00e8cnic La Fe","ror":"https://ror.org/01ar2v535","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I3019010403","https://openalex.org/I4210166036"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jos\u00e9 Andr\u00e9s Rom\u00e1n Ivorra","raw_affiliation_strings":["7Hospital Universitari I Polit\u00e8cnic La Fe, Valencia, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Hospital Universitari I Polit\u00e8cnic La Fe, Valencia, Spain","institution_ids":["https://openalex.org/I3019010403"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yanqing Hu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yanqing Hu","raw_affiliation_strings":["8Autolus Therapeutics, Rockville, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Autolus Therapeutics, Rockville, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109081750","display_name":"Wolfram Brugger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wolfram Brugger","raw_affiliation_strings":["9Autolus Therapeutics, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Autolus Therapeutics, Munich, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045405392","display_name":"Silvia Basilico","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Silvia Basilico","raw_affiliation_strings":["10Autolus Therapeutics, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Autolus Therapeutics, Basel, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003391497","display_name":"Davide Germano","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Davide Germano","raw_affiliation_strings":["10Autolus Therapeutics, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Autolus Therapeutics, Basel, Switzerland","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111821057","display_name":"Ruth J. Pepper","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289784979","display_name":"University College Hospital","ror":"https://ror.org/00wrevg56","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289784979","https://openalex.org/I1340918713"]},{"id":"https://openalex.org/I2801138448","display_name":"The Royal Free Hospital","ror":"https://ror.org/01ge67z96","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I169248724","https://openalex.org/I2801138448"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ruth Pepper","raw_affiliation_strings":["11Royal Free Hospital NHS Trust, London, United Kingdom","1University College London, London, United Kingdom","2University College London Hospital, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Royal Free Hospital NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I2801138448"]},{"raw_affiliation_string":"1University College London, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]},{"raw_affiliation_string":"2University College London Hospital, London, United Kingdom","institution_ids":["https://openalex.org/I1289784979","https://openalex.org/I45129253"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"146","issue":"Supplement 1","first_page":"815","last_page":"815"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9208999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9208999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10308","display_name":"Systemic Lupus Erythematosus Research","score":0.057500001043081284,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/systemic-lupus-erythematosus","display_name":"systemic lupus erythematosus","score":0.9599999785423279},{"id":"https://openalex.org/keywords/refractory-lupus","display_name":"refractory lupus","score":0.8820000290870667},{"id":"https://openalex.org/keywords/b-cell-depletion","display_name":"B-cell depletion","score":0.6930000185966492},{"id":"https://openalex.org/keywords/sledai-2k","display_name":"SLEDAI-2K","score":0.7870000004768372},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.671999990940094},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6570000052452087},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.6269999742507935},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.5770000219345093},{"id":"https://openalex.org/keywords/relapsed-refractory-disease","display_name":"relapsed/refractory disease","score":0.597000002861023}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8938999772071838},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.6966000199317932},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.6274999976158142},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6085000038146973},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.539900004863739},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.48330000042915344},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.45179998874664307},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.43860000371932983},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.43389999866485596},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4066999852657318},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.3601999878883362},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3521000146865845},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.35199999809265137},{"id":"https://openalex.org/C88879693","wikidata":"https://www.wikidata.org/wiki/Q217690","display_name":"Cumulative incidence","level":3,"score":0.34790000319480896},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3212999999523163},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.31520000100135803},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.3107999861240387},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.30570000410079956},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3012999892234802},{"id":"https://openalex.org/C2777866208","wikidata":"https://www.wikidata.org/wiki/Q415939","display_name":"Chlorambucil","level":4,"score":0.30070000886917114},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.2928999960422516},{"id":"https://openalex.org/C2778670039","wikidata":"https://www.wikidata.org/wiki/Q414004","display_name":"Nitrogen mustard","level":4,"score":0.27959999442100525},{"id":"https://openalex.org/C2775915377","wikidata":"https://www.wikidata.org/wiki/Q188297","display_name":"Lupus erythematosus","level":3,"score":0.2793000042438507},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2775000035762787},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.2752000093460083},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.27459999918937683},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.27390000224113464},{"id":"https://openalex.org/C151032500","wikidata":"https://www.wikidata.org/wiki/Q5194182","display_name":"Cumulative dose","level":2,"score":0.271699994802475},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.26420000195503235},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.2606000006198883},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.25440001487731934},{"id":"https://openalex.org/C2777408962","wikidata":"https://www.wikidata.org/wiki/Q1128050","display_name":"Hematopoietic stem cell transplantation","level":3,"score":0.25209999084472656},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.25029999017715454}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2025-815","doi":"https://doi.org/10.1182/blood-2025-815","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2025-815","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"CAR":[2,30,197,204,516,570,627,662],"T-cell":[3,31,517,571,628],"therapy":[4,32,110,167],"has":[5],"shown":[6],"promising":[7,613],"early":[8],"results":[9],"in":[10,43,66,75,91,267,291,296,418,454,472,502,553,608,657],"patients":[11],"(pts)":[12],"with":[13,33,68,73,96,108,146,168,330,442,450,486,509,526,538,620,623,652],"SLE":[14,129,137,313,435,611],"through":[15],"deep":[16],"depletion":[17],"of":[18,194,202,216,227,234,238,259,359,476,488,530,533,543,568,574,596,606,645],"the":[19,76,132,185,273,602],"B-cell":[20,46,365,540,578,635],"lineage,":[21],"including":[22,364],"plasmablasts.":[23],"Obe-cel":[24],"is":[25,85],"an":[26,128],"autologous":[27],"4-1BB-\u03b6":[28],"CD19-directed":[29],"a":[34,86,105,118,190,213,357,451,466,480,527,550,616,643],"fast":[35],"off-rate":[36],"binding":[37],"domain":[38],"and":[39,63,111,152,172,236,246,255,342,368,409,424,432,465,497,558,582,585,591,614,630,655],"demonstrated":[40],"clinical":[41,114,448,632],"efficacy":[42],"adult":[44],"relapsed/refractory":[45],"acute":[47],"lymphoblastic":[48],"leukemia":[49],"(Roddie":[50],"et":[51],"al.":[52],"NEJM":[53],"2024).":[54],"We":[55,269],"report":[56,270],"initial":[57],"safety,":[58],"preliminary":[59],"efficacy,":[60],"pharmacokinetics":[61],"(PK),":[62],"biomarker":[64,252],"analyses":[65],"pts":[67,92,126,188,264,278,304,325,352,389,428,441,478,505,576,658],"severe,":[69,97,310,609],"refractory":[70,98,154,311,610],"SLE,":[71,99],"treated":[72],"obe-cel":[74,181,276,425,607,621,640],"ongoing":[77,603],"Phase":[78,649],"I":[79,650],"CARLYSLE":[80,84,604],"study":[81,605],"(NCT06333483).":[82],"Methods:":[83],"single-arm,":[87],"open-label,":[88],"dose-finding":[89],"study,":[90],"aged":[93],"12\u201365":[94],"years":[95],"who":[100,659],"are":[101,612],"predicted":[102],"to":[103,121,155,163,184,209,356,521],"have":[104],"poor":[106],"outcome":[107],"standard":[109,157],"for":[112],"whom":[113],"trials":[115],"may":[116,641],"be":[117,665],"potential":[119],"option":[120],"improve":[122],"their":[123],"prognosis.":[124],"Eligible":[125],"had":[127,309,327,353,577],"diagnosis":[130],"per":[131],"2019":[133],"EULAR/ACR":[134],"criteria,":[135],"\u22658-point":[136],"Disease":[138],"Activity":[139],"Index":[140],"2000":[141],"(SLEDAI-2K)":[142],"score":[143,315],"at":[144,566],"screening":[145],"\u22651":[147,294],"major":[148],"SLE-related":[149],"organ":[150],"involvement":[151],"were":[153,160,265,386,398,420,437,588],"multiple":[156],"therapies.":[158],"Immunosuppressants":[159],"tapered":[161],"prior":[162,361],"apheresis.":[164],"Following":[165],"bridging":[166],"steroids":[169],"as":[170,189,542],"needed":[171],"lymphodepletion":[173],"(LD;":[174],"fludarabine":[175],"[25":[176],"mg/m2\u00d73],":[177],"cyclophosphamide":[178],"[1000":[179],"mg/m2]),":[180],"was":[182,206,220],"administered":[183,208],"first":[186,274],"six":[187],"single":[191],"flat":[192],"dose":[193,201,215],"50\u00d7106":[195],"(\u00b120%)":[196],"T-cells.":[198],"An":[199],"escalated":[200],"100\u00d7106":[203,661],"T-cells":[205,663],"then":[207],"additional":[210],"pts.":[211],"Only":[212],"maintenance":[214],"\u226410":[217],"mg/day":[218],"prednisone/equivalent":[219],"permitted":[221],"post":[222],"infusion.":[223,426],"Primary":[224],"endpoints:":[225,242],"incidence":[226],"dose-limiting":[228],"toxicities":[229],"(DLTs)":[230],"within":[231],"28":[232],"days":[233],"infusion,":[235],"frequency":[237],"adverse":[239,396],"events.":[240],"Secondary":[241],"disease":[243,430],"response":[244,355,483],"(SLEDAI-2K":[245,314],"Physician's":[247],"Global":[248],"Assessment":[249],"[PGA]":[250],"scores),":[251],"analyses,":[253],"PK,":[254],"pharmacodynamics.":[256],"Results:":[257],"As":[258],"9":[260],"July":[261],"2025,":[262],"10":[263],"enrolled":[266],"CARLYSLE.":[268],"data":[271,513,651,656],"on":[272],"6":[275,302,477,504],"infused":[277,303],"(data":[279],"cut:":[280],"17":[281],"March":[282],"2025;":[283],"follow-up":[284,445],"range:":[285,306,316],"1\u20138":[286],"months":[287],"[mos],":[288],"\u22653":[289,443],"mos":[290,444],"4":[292,406,440,575],"pts;":[293],"mo":[295],"2":[297],"pts).":[298],"At":[299],"baseline,":[300],"all":[301,503],"(age":[305],"19\u201350":[307],"years)":[308],"active":[312],"15\u201328),":[317],"class":[318,328],"III":[319],"or":[320,378,405,411],"IV":[321],"lupus":[322],"nephritis":[323],"(4":[324],"also":[326],"V),":[329],"elevated":[331],"urinary":[332],"protein-creatinine":[333],"ratio":[334],"(UPCR;":[335],"n=6;":[336],"median:":[337,346],"2.17":[338],"mg/mg":[339],"[range:":[340,349],"0.49\u20134.02])":[341],"serum":[343],"creatinine":[344],"(n=4;":[345],"128":[347],"\u00b5mol/L":[348],"123\u2013222]).":[350],"All":[351],"inadequate":[354],"median":[358],"5":[360],"immunosuppressive":[362],"treatments,":[363],"targeting":[366],"agents":[367],"calcineurin":[369],"inhibitors.":[370],"No":[371,427],"DLTs,":[372,625],"immune":[373],"effector":[374],"cell-associated":[375],"neurotoxicity":[376],"syndrome,":[377],"Grade":[379,391,403],"\u22652":[380],"cytokine":[381,547],"release":[382],"syndrome":[383],"(CRS)":[384],"events":[385,397],"seen;":[387],"3":[388,404],"experienced":[390,429,446],"1":[392],"CRS.":[393],"Most":[394],"treatment-emergent":[395],"low":[399],"grade":[400],"(\u22642).":[401],"Transient":[402],"neutropenia":[407],"(n=6),":[408],"transient":[410,551],"manageable":[412],"hypertension":[413],"(n=5;":[414],"pre-existing":[415],"medical":[416],"condition":[417],"n=3)":[419],"observed":[421,565,631],"after":[422],"LD":[423],"flares":[431],"no":[433,624],"rescue":[434],"medications":[436],"administered.":[438],"The":[439,634],"rapid":[447],"improvements":[449],"\u226510-point":[452],"reduction":[453,469],"SLEDAI-2K":[455],"scores":[456],"(range:":[457],"10\u201326":[458],"point":[459],"reductions":[460],"from":[461,601],"Month":[462],"[M]":[463],"3)":[464],"clinically":[467],"meaningful":[468],"(to":[470],"\u22641)":[471],"PGA":[473],"scores.":[474],"Three":[475,573],"achieved":[479],"complete":[481],"renal":[482],"by":[484,506],"M3":[485,581],"resolution":[487],"proteinuria":[489],"(achieved":[490],"UPCR":[491],"\u22640.5":[492],"mg/mg).":[493],"Complement":[494],"C3":[495],"normalized":[496],"anti-double-stranded":[498],"DNA":[499],"antibody":[500],"decreased":[501],"M1":[507,546],"compared":[508],"baseline":[510],"levels.":[511],"PK":[512],"indicated":[514],"robust":[515],"expansion":[518,532],"(median":[519],"time":[520,567],"maximal":[522,531,569],"expansion:":[523],"9.9":[524],"days),":[525],"geometric":[528],"mean":[529],"86,585":[534],"copies/\u03bcg":[535],"DNA,":[536],"coupled":[537],"undetectable":[539],"levels":[541,563],"Day":[544],"8.":[545],"profiling":[548],"showed":[549],"increase":[552],"interleukin":[554],"(IL)-6,":[555],"IL-8,":[556],"IL-10,":[557],"tumor":[559],"necrosis":[560],"factor":[561],"alpha":[562],"(peak":[564],"expansion).":[572],"recovery":[579],"between":[580],"M6;":[583],"double-negative":[584],"memory":[586],"B-cells":[587,593],"mostly":[589],"eliminated,":[590],"reconstituted":[592],"consisted":[594],"primarily":[595],"na\u00efve":[597],"B-cells.":[598],"Conclusions:Initial":[599],"findings":[600],"suggest":[615,638],"favorable":[617],"safety":[618],"profile":[619],"treatment,":[622],"pronounced":[626],"expansion,":[629],"benefit.":[633],"reconstitution":[636],"profiles":[637],"that":[639],"induce":[642],"reset":[644],"pathologic":[646],"autoimmunity.":[647],"Updated":[648],"longer":[653],"follow-up,":[654],"received":[660],"will":[664],"presented.":[666]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-12-05T00:00:00"}